A detailed history of Rmb Capital Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Rmb Capital Management, LLC holds 52,162 shares of ABBV stock, worth $9.39 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
52,162
Previous 51,679 0.93%
Holding current value
$9.39 Million
Previous $8.86 Million 16.21%
% of portfolio
0.24%
Previous 0.22%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$163.84 - $199.33 $79,134 - $96,276
483 Added 0.93%
52,162 $10.3 Million
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $782,308 - $913,561
-5,054 Reduced 8.91%
51,679 $8.86 Million
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $1.15 Million - $1.31 Million
7,175 Added 14.48%
56,733 $10.3 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $127,142 - $143,192
-924 Reduced 1.83%
49,558 $7.68 Million
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $199,717 - $231,201
1,495 Added 3.05%
50,482 $7.52 Million
Q2 2023

Aug 11, 2023

BUY
$132.51 - $164.9 $174,780 - $217,503
1,319 Added 2.77%
48,987 $6.6 Million
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $133,041 - $153,216
920 Added 1.97%
47,668 $7.6 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $552,686 - $662,816
3,996 Added 9.35%
46,748 $7.56 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $1.28 Million - $1.47 Million
-9,572 Reduced 18.29%
42,752 $5.74 Million
Q2 2022

Aug 01, 2022

BUY
$137.62 - $174.96 $2,201 - $2,799
16 Added 0.03%
52,324 $8.01 Million
Q1 2022

May 06, 2022

SELL
$131.98 - $163.75 $15,045 - $18,667
-114 Reduced 0.22%
52,308 $8.48 Million
Q4 2021

Jan 26, 2022

SELL
$107.43 - $135.93 $353,444 - $447,209
-3,290 Reduced 5.91%
52,422 $7.1 Million
Q3 2021

Oct 20, 2021

BUY
$106.4 - $120.78 $130,020 - $147,593
1,222 Added 2.24%
55,712 $6.01 Million
Q2 2021

Aug 13, 2021

SELL
$105.21 - $117.21 $7,890 - $8,790
-75 Reduced 0.14%
54,490 $6.14 Million
Q1 2021

May 12, 2021

SELL
$102.3 - $112.62 $91,865 - $101,132
-898 Reduced 1.62%
54,565 $5.91 Million
Q4 2020

Feb 11, 2021

SELL
$80.49 - $108.67 $961,453 - $1.3 Million
-11,945 Reduced 17.72%
55,463 $5.94 Million
Q3 2020

Nov 10, 2020

SELL
$85.91 - $100.83 $349,138 - $409,773
-4,064 Reduced 5.69%
67,408 $5.9 Million
Q2 2020

Aug 05, 2020

BUY
$73.37 - $98.18 $76,084 - $101,812
1,037 Added 1.47%
71,472 $7.02 Million
Q1 2020

May 11, 2020

SELL
$64.5 - $97.79 $24,768 - $37,551
-384 Reduced 0.54%
70,435 $5.37 Million
Q4 2019

Feb 13, 2020

SELL
$72.13 - $90.25 $39,815 - $49,818
-552 Reduced 0.77%
70,819 $6.27 Million
Q3 2019

Nov 12, 2019

SELL
$62.98 - $75.72 $868,872 - $1.04 Million
-13,796 Reduced 16.2%
71,371 $5.4 Million
Q2 2019

Aug 13, 2019

BUY
$65.7 - $83.98 $23,586 - $30,148
359 Added 0.42%
85,167 $6.19 Million
Q1 2019

May 15, 2019

SELL
$77.14 - $90.79 $94,342 - $111,036
-1,223 Reduced 1.42%
84,808 $6.84 Million
Q4 2018

Feb 13, 2019

BUY
$77.85 - $96.01 $485,005 - $598,142
6,230 Added 7.81%
86,031 $7.93 Million
Q3 2018

Nov 14, 2018

BUY
$88.91 - $98.84 $29,429 - $32,716
331 Added 0.42%
79,801 $7.55 Million
Q2 2018

Aug 13, 2018

SELL
$89.78 - $106.23 $88,971 - $105,273
-991 Reduced 1.23%
79,470 $0
Q1 2018

May 14, 2018

SELL
$92.01 - $123.21 $5.06 Million - $6.77 Million
-54,950 Reduced 40.58%
80,461 $7.62 Million
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $6.87 Million - $7.53 Million
76,696 Added 130.62%
135,411 $13.1 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $1.28 Million - $1.64 Million
18,367 Added 45.52%
58,715 $5.22 Million
Q2 2017

Aug 14, 2017

BUY
N/A
40,348
40,348 $2.93 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Rmb Capital Management, LLC Portfolio

Follow Rmb Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rmb Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rmb Capital Management, LLC with notifications on news.